INVOKAMET XR (Janssen Pharmaceuticals, Inc.)
Welcome to the PulseAid listing for the INVOKAMET XR drug offered from Janssen Pharmaceuticals, Inc.. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Biguanide [EPC],Biguanides [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Janssen Pharmaceuticals, Inc. |
| NON-PROPRIETARY NAME: | canagliflozin and metformin hydrochloride |
| SUBSTANCE NAME: | CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Biguanide [EPC],Biguanides [Chemical/Ingredient] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED, EXTENDED RELEASE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-09-20 |
| END MARKETING DATE: | 0000-00-00 |
INVOKAMET XR HUMAN PRESCRIPTION DRUG Details:
| Item Description | INVOKAMET XR from Janssen Pharmaceuticals, Inc. |
| LABELER NAME: | Janssen Pharmaceuticals, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 50; 500(mg/1; mg/1) |
| START MARKETING DATE: | 2016-09-20 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50458-940_631fdfe9-0aae-4f28-a8bb-5d52ed3c25f2 |
| PRODUCT NDC: | 50458-940 |
| APPLICATION NUMBER: | NDA205879 |
Other CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers:
